Shaily Engineering Plastics Limited Launches Semaglutide Combination Product Using ShailyPen Neo™ Technology
Shaily Engineering Plastics Limited, a manufacturer of drug delivery systems, announced the successful launch of a combination product featuring a generic version of Semaglutide injection. This product, which incorporates Shaily's proprietary spring-driven ShailyPen Neo™ pen platform, has achieved significant regulatory milestones globally.Shaily’s strategic partner, Orbicular Pharmaceutical Technologies, collaborated with the customer to launch the combination product in Canada. The product has been commercially available in India since March 2026 and has also secured USFDA Tentative Approval, alongside Health Canada Notice of Compliance and Indian Regulatory Approval.
ShailyPen Neo™ is notable for being among a rare class of commercially available spring-driven pen injectors worldwide. The platform functions as a high-performance, variable and fixed dose system, offering full compatibility with standard ISO 3 mL cartridges, accommodating both 3 mL and 1.5 mL fills. Shaily's involvement in this program encompasses the full design, development, manufacturing, and supply of the necessary device components for the approved combination product.
The key features and regulatory statuses of the combination product are outlined below:
| Regulatory Approvals | Device Platform | Cartridge Format |
|---|---|---|
| USFDA TA | ShailyPen Neo™ | ISO 3 mL |
| Health Canada | Variable & Fixed Dose | 1.5 mL fill |
| India CDSCO |
Amit Sanghvi, Managing Director of Shaily Engineering Plastics Limited, commented on the achievement, noting the complexity of the technology. "ShailyPen Neo™ did not happen by accident - spring-driven pen injector technology sits within a highly restricted IP environment, and bringing a platform of this caliber to regulatory approval was never going to be easy. We recognized early that spring-actuated pen injectors would become a critical enabler in injectable therapies and made a genuinely bold bet: full-scale investment from design through to industrial manufacturing."
Shaily Engineering Plastics Limited operates across three major industry verticals, specializing in manufacturing high precision components and assemblies using high performance engineering polymers. The company's healthcare business focuses specifically on the design, development, and precision manufacturing of complex drug delivery systems, including autoinjectors and pen injectors, for the global pharmaceutical sector.
Shaily partners with leading pharmaceutical companies to co-develop and commercially supply validated combination product solutions that meet the rigorous regulatory requirements of international healthcare markets. Shaily is listed on the National Stock Exchange of India (NSE: SHAILY) and BSE Limited (Scrip Code: 501423).
SHAILY Stock Price Movement
Shares of Shaily Engineering Plastics Limited are rallying as of 3:26 PM, gaining 3.77% today in live trading to reach ₹2736.2. The stock hits its 52-week high, supported by high investor interest that saw 963,090 shares traded.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: